Ronald Sugar - Amgen Independent Director
| AMGN Stock | MXN 4,651 201.54 4.53% |
Director
Dr. Ronald D. Sugar, Ph.D., is an Independent Director of the Company. Ronald D. Sugar is the retired Chairman of the Board and Chief Executive Officer of Northrop Grumman Corporationrationration, a global aerospace and defense company, having held these posts from 2003 through 2009. Dr. Sugar was a director of Chevron Corporationrationration, a petroleum, exploration, production and refining company, since 2005, serving as the lead director and on the Management Compensation Committee and chairing the Board Nominating and Governance Committee Apple Inc., a manufacturer and seller of, among other things, personal computers, mobile communication and media devices, since 2010, chairing the Audit and Finance Committee and of Air Lease Corporationrationration, an aircraft leasing company, since 2010, chairing the Compensation Committee and serving on the Governance Committee. Since 2010, he was a senior advisor to Ares Management LLC, a privatelyheld asset manager and registered investment advisor. In 2014, Dr. Sugar joined the Temasek Americas Advisory Panel of Temasek Holdings Limited, a privatelyheld investment company based in Singapore since 2010.
| Age | 69 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michele Ashby | McEwen Mining | 59 | |
| Hadi Ibrahim | Grupo Sports World | 42 | |
| KarlLudwig Kley | Verizon Communications | 66 | |
| Donald Quick | McEwen Mining | 62 | |
| John Teets | Air Transport Services | 45 | |
| Fabian Castro | Grupo Sports World | N/A | |
| Mark Bertolini | Verizon Communications | 61 | |
| Richard Rexach | Verizon Communications | 63 | |
| Zhongxi Li | Taiwan Semiconductor Manufactur | N/A | |
| Laura Peterson | Air Transport Services | 58 | |
| Sachin Lawande | DXC Technology | 50 | |
| Meiling Chen | Taiwan Semiconductor Manufactur | N/A | |
| Zhenrong Shi | Taiwan Semiconductor Manufactur | N/A | |
| Allen Ambrose | McEwen Mining | 58 | |
| Daniel Schulman | Verizon Communications | 60 | |
| Leanne Baker | McEwen Mining | 64 | |
| Thomas Engibous | Taiwan Semiconductor Manufactur | 61 | |
| Robert Woods | DXC Technology | 62 | |
| Wilfrido Mejorada | Grupo Sports World | N/A | |
| Arthur Lichte | Air Transport Services | 64 | |
| Melanie Healey | Verizon Communications | 56 | |
Management Performance
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, VP Officer | ||
| Frank Herringer, Independent Director | ||
| Nancy Grygiel, Sr Officer | ||
| Francois Carbonnel, Independent Director | ||
| Rebecca Henderson, Independent Director | ||
| Annette Such, Chief Accounting Officer | ||
| Sanders Williams, Independent Director | ||
| Vance Coffman, Lead Independent Director | ||
| David Reese, Executive Vice President - Research and Development | ||
| Tyler Jacks, Independent Director | ||
| Brian McNamee, Executive Vice President - Full Potential Initiatives | ||
| Gregory Garland, Independent Director | ||
| Charles Holley, Director | ||
| Esteban Santos, Executive Vice President Operations | ||
| Jonathan Graham, Senior Vice President General Counsel, Secretary | ||
| Sean Harper, Executive Vice President - Research and Development | ||
| Mike Zahigian, VP Officer | ||
| Ellen Kullman, Director | ||
| Frank Biondi, Independent Director | ||
| Arvind Sood, IR Contact Officer | ||
| David Meline, CFO and Executive VP | ||
| Ronald Sugar, Independent Director | ||
| Stuart Tross, Senior Vice President - Human Resources | ||
| Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | ||
| Murdo Gordon, Executive Vice President of Global Commercial Operations | ||
| Peter Griffith, Ex CFO | ||
| Wanda Austin, Independent Director | ||
| Robert Eckert, Independent Director | ||
| Madhavan Balachandran, Executive VP of Operations | ||
| Lori Johnston, Senior Vice President - Human Resources | ||
| Brian Druker, Independent Director | ||
| Cynthia Patton, Senior Vice President Chief Compliance Officer | ||
| Greg Garland, Independent Director | ||
| Robert Williams, Independent Director | ||
| Judith Pelham, Independent Director | ||
| David Baltimore, Independent Director | ||
| Fred Hassan, Director | ||
| David Piacquad, Senior Vice President - Business Development | ||
| Anthony Hooper, Executive VP of Global Commercial Operations | ||
| David MD, Ex RD |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 3.36 T | |||
| Shares Outstanding | 533.98 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.38 % | |||
| Price To Earning | 267.53 X | |||
| Price To Book | 40.33 X |
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
| 0.77 | ROGN | Roche Holding AG | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |